CSL Limited (CSLLY) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Melbourne, VIC, Australia. El CEO actual es Gordon Naylor DipCompSc.
CSLLY tiene fecha de IPO 2009-12-29, 32,698 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $95.92B.
CSL Limited is a global biopharmaceutical company headquartered in Parkville, Australia, with operations across the United States, Europe, China, and other international markets. The company operates through two primary divisions: CSL Behring, which specializes in plasma-derived and recombinant therapies for immunodeficiency, bleeding disorders, hereditary angioedema, and neurological conditions, and Seqirus, which focuses on non-plasma biotherapeutics and influenza-related products. CSL Limited researches, develops, manufactures, and distributes a comprehensive portfolio of biopharmaceutical products while also generating revenue through licensing and royalty agreements. Founded in 1916, the company has established itself as a leader in the biopharmaceutical industry through its innovative therapeutic solutions and global market presence.
